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Conclusions: RT±CT achieve good LC rates in anal canal cancer 
patients. In our experience, local response and LC statistically 
influenced the Cancer Specific Survival and the risk of systemic 
relapse. High acute skin toxicity rates probably impose to tailor 
volumes and techniques of irradiation following the patient and tumor 
characteristics (more tailored indications for inguinal RT?). 
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Purpose/Objective: Chemoradiation is worldwide considered the 
standard treatment of anal cancer, with a high rate of sphincter 
preservation, local control and survival. However, this strategy often 
leads to significant acute morbidity, playing a negative impact on 
clinical outcome. New technological advances could improve dose 
delivery and therapeutic index ratio. As IMRT allows simultaneous 
integrated boost (SIB) of higher RT doses to the gross tumor volume 
and lower doses to normal tissue, our purpose is to evaluate if this 
recently introduced technique can result in a better outcome in terms 
of tolerance and clinical results for patients affected by anal 
carcinoma. 
Materials and Methods: Between February 2009 and October 2012, 31 
patients, median age 62 years, with stage I (6 pts), II (6 pts), IIIA (8 
pts), IIIB (11 pts) were treated with RT±CT. 19 patients underwent 2 
courses of MMC and 5 FU (during the first and last week of RT); 3 pts 
received Capecitabine concurrent with RT; 3 pts received 
Capecitabine and MMC. IMRT with SIB was delivered by Helical 
Tomotherapy (HT) in 24 patients and by a Linac-based step & shoot 
technique in 7. The prescribed doses were 50.6-55 Gy to CTV1 
(primary tumor, involved nodes and high risk area) and 41.4-45 Gy to 
CTV2 (low risk subclinical disease), in 23-25 daily fractions. 
Megavoltage CT scans were obtained for patient alignment before 
each treatment in the group treated with HT while weekly portal 
images were performed in the other group. The clinical status during 
RT was analyzed through the evaluation of supportive care type 
defined by analgesic need. 
Results: All patients received the prescribed dose and none had 
treatment breaks due to acute toxicity, except for one, who refused 
to conclude treatment, receiving 50.6 Gy on CTV1 in 23 fractions. For 
all patients, dose volumes results for CTVs are reported in the table. 
Mean doses to bladder and bowel were respectively 28.5 and 16.4 Gy. 
The median follow-up is 12 months (range 1-36). The most significant 
severe genitourinary acute toxicities reported at treatment end were 
grade 3 vaginal bleeding (3%) and grade 2 vaginal burn (6%). 
Cutaneous grade 3 erythema was recorded in 20% of patients and 
grade 2 gastrointestinal toxicities in 16%. Generally, skin toxicity 
appeared in the last week of RT and recovered in 2 weeks. 16 (53%) 
patients needed analgesic support (tramadol, codeine or major 
opioids). At a minimum FU of 4 months, 22 patients are evaluable for 
clinical response: 19 (86%) patients achieved complete response (CR), 
2 patients underwent local progression after initial partial response 
(PR) and one patient had progressive disease (PD). One patient died 
for PD. 
 
 
 
 
 
 
 
 
 
 
Conclusions: IMRT with SIB achieves great homogeneity in the dose 
distribution and a significantly good sparing of the organs at risk, also 
shortening total treatment time. The combined chemo-radiotherapy 
also shows excellent results in terms of toxicity and local control.  
 
 POSTER: CLINICAL TRACK: GENITOURINARY 
(PROSTATE INCLUDED)  
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Purpose/Objective: Stereotactic Body Radiation Therapy (SBRT) take 
advantage of the prostate low a/b ratio to deliver a large radiation 
dose in few fractions. Recent technological developments, combined 
with modern understanding on prostate radiobiology have generated 
enthusiasm for hypofractionated regimens. We report our preliminary 
results with Cyberknife stereotactic radiosurgery in patients with 
clinically localized prostate cancer. 
 Materials and Methods: From July 2007 to October 2011, 107 
patients with a median age of 75 (range 60– 86) years, a T1c –T2 b 
prostate cancer were treated with Cyberknife stereotactic 
radiosurgery at our institution. The majority of patients 59 (55%) were 
low risk , 28 pts (26%) were intermediate risk and 19 pts (19%) were 
high risk patients using the NCCN criteria . Pre-treatment PSAs ranged 
from 1.75 to 23.88 ng.ml (median 7.4 ng.ml). Among the entire study 
cohort 7 of 19 high risks patients received androgen deprivation 
therapy (ADT), ADT was not administered to any low – intermediate 
risk patients A prescribed dose of 38 Gy in four fractions was delivered 
to the PTV, which was defined as the prostate (plus seminal vesicles 
in High risk patients) expanded 3 mm posteriorly and 5 mm elsewhere. 
Real-time intrafractional motion tracking was used. Biochemical 
control was assessed using the nadir+2 (Phoenix) definition.  
Results: All patients were placed on A-blockade medication at the 
beginning of Cyberknife radiosurgery treatment. Acute side effects 
were generally mild and resolved shortly after treatment. No rtog 
grade 4 acute or late ractal/urinary complications was observed. 3 
patients developed Grade 3 late urinary toxicity following repeated 
urological instrumentation, including cistoscopy and urethral 
dilatation. Four patients, one with prior Turp, experienced 
incontinence, one 9 months after treatment, two 12 months after 
treatment, one 27 months later. One patient experienced rectal 
incontinence 12 months after treatment. The actuarial median follow 
up is 30 months (range 12 – 60 months). The four years actuarial psa 
relapse free survival rate is 93.9% (CI: 88.0%-99..8%). To date 5 
patients failed biochemically. One low risk patient revealed local 
relapse 30 months after Cyberknife treatment. One high risk patient 
developed bone metastases, in 2 intermediate and in 1 high risk 
patient we observed nodal metastases. All patients are alive except 
four died of unrelated causes. 
Conclusions: Cyberknife SBRT produces excellent biochemical control 
rates at up to 4 years with mild toxicity and minimal impact on quality 
of life. Median PSA levels compare favourably with other radiation 
Volume/Gy Prescription 
Dose (Gy) 
Mean 
Dose 
Max 
Dose 
Min 
Dose 
CTV55 55 54.9 56.8 51.4 
CTV50.6 50.6 51 52.9 47.7 
CTV45 45 47 55.9 38.4 
CTV41.4 41.4 42.5 52 39.3 
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modalities and strongly suggest durability of our results. Further 
follow up is needed to confirm this.  
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Purpose/Objective: To update a Hypofractionated Tomotherapy 
Treatment (HTT) feasibility-study, by evaluation of toxicity and 
outcome, in lymph nodal relapse of patients (pts) already treated for 
prostate cancer. The role of 11CCholine PET/CT in detecting prostate 
cancer recurrence and as a 'guide' for Tomotherapy treatment was 
also evaluated. 
Materials and Methods: From January 2005 to August 2012, 49 
prostate cancer pts with biochemical recurrence and evidence of 
lymph nodal relapse at 11CCholine PET/CT scan (PET/CT0) were 
treated with moderately hypofractionated Tomotherapy. All pts had 
undergone previous prostatectomy, radical radiation therapy (RT) or 
prostatectomy + RT and all were currently receiving systemic therapy. 
One patient was treated 3 times, two patients twice: the total 
number of therapies was 53. In 49/53 cases PET/CT0 detected 
metastases (LNMs) at para-aortic and/or pelvic level, in 4 cases at the 
mediastinal level. Pelvic and/or lombo-aortic lymph nodes were 
treated to 51.8Gy/28 fractions and PET/CT0 positive lymph nodes 
were treated with higher dose using a simultaneous integrated boost. 
A Mega-Voltage CT scan (MVCT) was performed before each fraction 
to allow correct patient repositioning in order to reduce PTV margin 
and side effects to surrounding tissues. The doses ranged from 42 Gy 
in 6 fractions to 74.2 Gy in 28 fractions. To evaluate treatment 
efficacy, PSA serum measurement (PSA1) (all pts) and 11CCholine 
PET/CT(PET/CT1) (n=19) were performed after treatment and 
compared to basal evaluations. 
Results: In 17/49 pts (53 therapies) 6 genito-urinary [GU] and 11 
upper-gastro intestinal [uGE] G1 acute toxicities were recorded. Only 
5 G2 uGE and 2 G2 GU were observed. 3 pts had G1 rectum toxicity 
and 3 pts G1 erythema. No G3-G4 acute side effects were registered. 
Among the 41 pts with follow-up longer than 3 months, 5 had G1 late 
toxicity (1uGE and 4GU), 3 presented G2GU toxicity, one G2 rectal 
toxicity and 3 G3 GU toxicity. With a median follow-up of 24 months 
(range: 0-88)37/41 pts had a significant reduction of PSA value after 
HTT. Of the 19 pts with PET/CT1 evaluation, 14 had Complete 
Metabolic Response and 2 Partial Metabolic Response. During follow-
up, only 3 of the 41 evaluable pts had progression in the irradiated 
area and 7 in other sites. One died of tumour progression. Half of the 
patients in complete remission maintained good PSA control even 
after suspending their medical treatment. Mean Overall survival was 
31.73 months; Overall Survival at 36 months was 85.7%, PFS at 36 
months was 32.8%. 
Conclusions: These preliminary data show that HTT 11CCholine 
PET/CT-guided with IGRT for precise repositioning is safe and 
effective in lymph nodal relapse of prostate cancer pts and could be a 
valid alternative to chemotherapy. Although further evaluations are 
necessary, the good rate of local control suggests that HTT treatment 
guided by 11CCholine PET/CT images maybe reasonably proposed in 
these patients. 
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Purpose/Objective: International Prostate Symptoms Score (IPSS) at 
baseline and at one year follow-up were compared in Active 
Surveillance (AS) vs radical radiation (RT) pts. Aim of the present 
analysis was to determine if the expected changes in IPSS after RT has 
also psychological distress or age-related components in addition to 
radio-induced bladder/urethral toxicity. 
Materials and Methods: Between Dec 09 and Jul 12, 211 RT pts 
completed IPSS at baseline (T0) and 86/211 at one year from RT end 
(T1). Between Nov 07 and Nov 12, 145 AS pts completed the IPSS 
questionnaire at T0 and 57/145 at one year from AS enrolment (T1). 
IPSS was divided into 5 groups: =0 (no symptoms, symp), 1-7 (mild 
symp), 8-14 (mild to moderate symp), 15-19 (moderate symp) and 20-
35 (severe symp). Possible associations between clinical variables and 
IPSS were determined through Pearson correlation coefficient. 
Clinically significant changes over time were defined as at least 4, 6, 
8 IPSS increase, defined as mild, moderate and severe worsening, 
respectively. Z-test for proportions was used to investigate 
statistically significant differences in % of pts with mild to severe GU 
symp worsening in the two cohorts (AS vs RT). 
Results: Mean age: 65 vs 70 in AS and RT. Mean initial PSA: 5.1 vs 12.8 
ng/ml, AS vs RT. AS pts were all ≤low-risk; RT pts: 26% low, 41.5% 
intermediate and 32.5% high-risk. Figure 1 shows the distribution of 
IPSS classes at T0 stratified by age and cohort. Youngest RT pts 
reported the best IPSS, while AS pts >70yrs showed the highest rate 
(24%) of moderate/severe symp. 
No significant correlation was found for age, clinical stage, initial PSA 
and BMI.  35% vs 21% pts (in AS and RT respectively, p=0.06) reported 
at least 4-point IPSS worsening, 24% vs 15% (p=0.16) and 12% vs 9% 
(p=0.58) at least 6 and 8-point increase, respectively. AS pts with IPSS 
at 2 yr follow-up (T2) showed that 86% of pts with 4-point worsening 
at T1 completely recovered to T0 level (90% and 83% for 6 and 8-
point). 
  
Conclusions: Our prostate cancer RT population reported less GU 
symp (as measured by IPSS) at T0 with respect to the AS population. % 
of pts with mild to severe GU symp worsening after 1 yr follow-up was 
higher in AS, but differences were not statistically significant.  It has 
to be underlined that T1 AS IPSS measurement was performed one 
month after prostate re-biopsy (as established by AS protocol) and 
worsening of GU symp can be caused by biopsy-related acute toxicity. 
This hypothesis is confirmed if AS IPSS at 2 yrs is considered: 85-90% of 
pts recovered to T0 IPSS level. With respect to RT IPSS scores, the use 
of neo-adjuvant hormone therapy (40% of pts) could explain both T0 
and T1 better IPSS in this cohort. Psychological distress or age-related 
components do not seem to play a significant role in GU function 
worsening at 1 yr in RT cohort. Longer follow-up is needed to 
determine the true impact of these variables on late GU radio-induced 
changes. 
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Purpose/Objective: An advantage for the use of carbogen and 
nicotinamide to overcome tumour hypoxia during radiotherapy (RT) 
has been demonstrated for bladder and head and neck cancers (1, 2). 
The aims of this trial are: (1) to evaluate the safety of applying this 
treatment strategy to patients receiving RT for high risk prostate 
cancer; (2) to establish the biochemical progression free survival in 
patients treated with hypoxia modification and (3) to study the 
changes in the tumour micro-environment using multi-parametric 
magnetic resonance (MR) imaging at different time points during the 
